Flupentixol

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Flupentixol

Examples of brand names: Fluanxol [DE]

ATC code: N05AF01

Main use (for orientation): Psychoses

Documented research summary

Mouse studies show THC-enhanced catalepsy or hypothermia with flupentixol; no human pharmacokinetic confirmation. Clinical cannabis cohorts are confounded by illness, use and other substances.

Uncertainties and limitations

Cell/animal models and uncontrolled observations cannot be directly applied to clinical dosing decisions.

Rare cannabinoids within the scope of 28 remain poorly documented where pair-specific findings are absent.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0325

Type of result: Preclinical

Observation: cis(Z)-Flupentixol enhanced THC catalepsy; do not equate the inactive trans(E) isomer.

Mechanism: Pharmacodynamic enhancement of catalepsy; GABA modulation in a mouse model.

Study type: Mouse experiment; abstract

Context studied: THC 10 mg/kg intraperitoneally.

Clinical interpretation: Clinical significance undetermined

Limitations and uncertainties: Not transferable to humans or everyday doses; full text inaccessible.

Original sources for this finding: Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. [CA_P_2854226]

THC – laboratory and animal studies

Finding ID: B0326

Type of result: Preclinical

Observation: THC hypothermia enhanced in mice.

Mechanism: Pharmacodynamic enhancement of hypothermia; alpha-adrenoceptor component proposed.

Study type: Mouse experiment; abstract

Context studied: THC 5 mg/kg i.p.; flupentixol 0.375 mg/kg s.c.

Clinical interpretation: Clinical significance undetermined

Limitations and uncertainties: Do not infer a D2/CYP explanation from the experiment; full text inaccessible.

Original sources for this finding: The hypothermic response of mice to delta-9-tetrahydrocannabinol is enhanced by chlorpromazine, thioxanthenes, alpha-adrenoceptor antagonists and pentolinium but not by SCH 23390 or sulpiride. [C_PR_2895430]

References and access status

[C_LABEL_D0134] Fluanxol0.5/1mg

Original source / bibliographic reference

Authors: Pharmaceutical company not separately entered in the source field; product / official product information identified by title and URL

Year: 2021

Source type: Product information / SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_2854226] Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice.

Original source / bibliographic reference

Authors: Pertwee RG, Greentree SG, Swift PA.

Year: 1988

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1016/0028-3908(88)90029-9

PMID: 2854226

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_2895430] The hypothermic response of mice to delta-9-tetrahydrocannabinol is enhanced by chlorpromazine, thioxanthenes, alpha-adrenoceptor antagonists and pentolinium but not by SCH 23390 or sulpiride.

Original source / bibliographic reference

Authors: Pertwee RG, Hedley D, McQueen AS, Gentleman SM.

Year: 1988

Source type: Primary source, abstract read

DOI: 10.1016/0028-3908(88)90164-5

PMID: 2895430

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_35108745] The associations of cannabis and methamphetamine use with cognitive performance over the first 2 years of treatment in schizophrenia spectrum disorders.

Original source / bibliographic reference

Authors: Scheffler F, Phahladira L, Hendrikse CB, du Plessis S, Asmal L, Luckhoff HK, Smit AM, Olivier MR, Emsley R.

Year: 2022

Source type: Primary source, abstract read

DOI: 10.1111/eip.13272

PMID: 35108745

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_PMC7234658] T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT

Original source / bibliographic reference

Authors: Scheffler F, Luckhoff H, du Plessis S, Phahladira L, Asmal L, Kilian S, Emsley R.

Year: 2020

Source type: Primary source, abstract read

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed Central – archived text

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility